Cargando…

Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells

PD-1 is a target of cancer immunotherapy but responses are limited to a fraction of patients. Identifying patients with T cells subjected to PD-1-mediated inhibition will allow selection of suitable candidates for PD-1-blocking therapy and will improve the therapeutic success. We sought to develop a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bardhan, Kankana, Aksoylar, Halil-Ibrahim, Le Bourgeois, Thibault, Strauss, Laura, Weaver, Jessica D., Delcuze, Bethany, Charest, Alain, Patsoukis, Nikolaos, Boussiotis, Vassiliki A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872651/
https://www.ncbi.nlm.nih.gov/pubmed/31754127
http://dx.doi.org/10.1038/s41598-019-53463-0
Descripción
Sumario:PD-1 is a target of cancer immunotherapy but responses are limited to a fraction of patients. Identifying patients with T cells subjected to PD-1-mediated inhibition will allow selection of suitable candidates for PD-1-blocking therapy and will improve the therapeutic success. We sought to develop an approach to detect PD-1-mediated inhibitory signaling. The cytoplasmic tail of PD-1 contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) encompassing Y223 and an immunoreceptor tyrosine-based switch motif (ITSM) encompassing Y248, which is indispensable for interaction of SHP-2 and delivery of PD-1 inhibitory function. We generated an antibody specific for phosphorylated PD-1-Y248 and examined PD-1pY248(+) (pPD-1) expression in human T cells. pPD-1 was upregulated by TCR/CD3 + CD28 stimulation and simultaneous PD-1 ligation. pPD-1(+)CD8(+) T cells were identified in human peripheral blood and had impaired effector function. pPD-1(+) T cells were also detected in tumor-draining lymph nodes of tumor bearing mice and in biopsies of patients with glioblastoma multiform. Detection of pPD-1(+) T cells might serve as a biomarker for identification of T cells subjected to PD-1-mediated immunosuppression.